|
(6) Molecular mechanisms explaining premalignant changes in the etiology of melanoma
|
1R21CA208736-01A1
|
$146,000
|
|
MURPH, MANDI
|
UNIVERSITY OF GEORGIA
|
|
(7) Novel imaging devices for measurement and control of tumor microenvironments
|
1R01CA216248-01
|
$565,675
|
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
(PQ #4) Single cell barcoding for studies of study clonal evolution in glioblastoma
|
5R01CA190121-05
|
$362,088
|
|
VERHAAK, ROELAND
|
JACKSON LABORATORY
|
|
(PQ1) Cellular senescence as an initiating event in malignant transformation
|
1R21CA206013-01A1
|
$203,400
|
|
DAVID, GREGORY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(PQ1) Characterization of Premalignant Fields in a Murine Model of Head and Neck and Esophageal Cancers
|
5R01CA205258-02
|
$464,261
|
|
GUDAS, LORRAINE
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection
|
5R01CA206476-02
|
$772,521
|
|
CHIAO, ELIZABETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years
|
5R01CA206477-02
|
$756,373
|
|
PALEFSKY, JOEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years
|
5R01CA206477-02
|
$756,373
|
$756,373
|
PALEFSKY, JOEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQ4)HIV and Aging Mechanisms for Hepatocellular Cancer
|
5R01CA206465-02
|
$527,068
|
$527,068
|
JUSTICE, AMY
|
YALE UNIVERSITY
|
|
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity
|
5R01CA205101-02
|
$388,402
|
|
SKALA, MELISSA
|
MORGRIDGE INSTITUTE FOR RESEARCH, INC.
|
|
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
|
1R01CA216273-01
|
$701,924
|
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
|
1R01CA216273-01
|
$701,924
|
$175,481
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy
|
5R01CA206028-02
|
$342,964
|
|
GEWIRTZ, DAVID
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy
|
1R01CA205166-01A1
|
$536,312
|
|
KELLEY, MARK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQA2) Exploring the role of sarcopenia in obesity and breast cancer survival
|
5R01CA184953-04
|
$607,944
|
|
CAAN, BETTE
|
KAISER FOUNDATION RESEARCH INSTITUTE
|
|
(PQA2): Escape from breast tumor dormancy: convergence of obesity and menopause
|
5R01CA185530-04
|
$367,275
|
$183,638
|
MOSES, MARSHA
|
BOSTON CHILDREN'S HOSPITAL
|
|
(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma
|
5R01CA183776-05
|
$309,175
|
|
LESSNICK, STEPHEN
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
|
(PQB-3) Driver gene-induced inflammation in pancreatic cancer development
|
5R01CA184926-04
|
$765,544
|
|
JAFFEE, ELIZABETH
|
JOHNS HOPKINS UNIVERSITY
|
|
(PQB-4) Opposing Effects of the SASP in Cancer Progression
|
5R01CA184572-04
|
$329,925
|
$82,481
|
HERBIG, UTZ
|
RBHS-NEW JERSEY MEDICAL SCHOOL
|
|
(PQC-1) Driver Events In IBD-Associated Neoplastic Progression
|
5R01CA190040-04
|
$613,138
|
|
MELTZER, STEPHEN
|
JOHNS HOPKINS UNIVERSITY
|
|
(PQC1) Accelerated biological aging and colon polyp to cancer progression
|
5R01CA194663-03
|
$401,482
|
$401,482
|
GRADY, WILLIAM
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
(PQC2) Optical Hallmarks of Aggressive Clones Within Oral Field Cancerization
|
5R01CA185207-04
|
$640,637
|
|
RICHARDS-KORTUM, REBECCA
|
RICE UNIVERSITY
|
|
(PQC3) Ethnicity-determined immune response and DCIS outcome
|
5R01CA194600-03
|
$675,664
|
|
BADVE, SUNIL
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQD-3) Spatiotemporal Molecular Interrogation of Early Metastatic Evolution In Situ
|
5R01CA194697-03
|
$347,700
|
|
ZHANG, SIYUAN
|
UNIVERSITY OF NOTRE DAME
|
|
(PQD-5) Patient derived orthotopic xenograft models for drug response prediction
|
5R01CA185402-04
|
$318,923
|
|
LI, XIONAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
|
5R01CA185151-04
|
$613,546
|
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
|
5R01CA184922-04
|
$553,684
|
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
(PQD5) A novel genetic strategy to predict efficacy of anti-CD20 antibodies
|
5R01CA185372-04
|
$321,625
|
|
RICHARDS, KRISTY
|
CORNELL UNIVERSITY
|
|
(PQD5) Avatar-directed Treatment for Ovarian Cancer
|
5R01CA184502-04
|
$714,297
|
|
WEROHA, SARAVUT
|
MAYO CLINIC ROCHESTER
|
|
(PQD5) imaging systemic tissue injuries induced by anticancer drugs
|
5R01CA185214-04
|
$496,930
|
|
ZHAO, MING
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
(PQD5) Mass Profiling Melanoma Responses to Improve Therapy Choices and Prognosis
|
5R01CA185189-04
|
$483,693
|
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling
|
5R01CA185353-04
|
$405,890
|
|
KIM, WILLIAM
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
(PQD6) Hypothalamic Inflammation in the Initiation of Cachexia
|
5R01CA184324-04
|
$422,399
|
|
MARKS, DANIEL
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
$126,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
1 of 3 Interdisciplinary Collaboratory for Enhancing Translational Therapeutics Utilizing Biologically, Immunologically, and Metabollically Relevant Models of Breast Cancer
|
5R01CA195904-03
|
$555,499
|
|
MURPHY, WILLIAM
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
1 of 3 Interdisciplinary Collaboratory for Enhancing Translational Therapeutics Utilizing Biologically, Immunologically, and Metabollically Relevant Models of Breast Cancer
|
5R01CA195904-03
|
$555,499
|
$555,499
|
MURPHY, WILLIAM
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
2017 Cell Contact and Adhesion Gordon Research Conference and Gordon Research Seminar
|
1R13CA216892-01
|
$3,750
|
|
MCCLATCHEY, ANDREA
|
GORDON RESEARCH CONFERENCES
|
|
2017 Cholangiocarcinoma Foundation Annual Conference
|
1R13CA213778-01
|
$5,000
|
|
LINDSEY, STACIE
|
CHOLANGIOCARCINOMA FOUNDATION
|
|
2017 Directed Cell Migration Gordon Research Conference and Gordon Research Seminar
|
1R13CA213855-01
|
$2,000
|
|
MONTELL, DENISE
|
GORDON RESEARCH CONFERENCES
|
|
2017 Mammary Gland Biology Gordon Research Conference & Gordon Research Seminar
|
1R13CA216888-01
|
$10,000
|
|
FORD, HEIDE
|
GORDON RESEARCH CONFERENCES
|
|
2017 Stem Cells and Cancer Gordon Research Conference and Gordon Research Seminar
|
1R13CA213446-01
|
$4,000
|
$4,000
|
RUDOLPH, K. LENHARD
|
GORDON RESEARCH CONFERENCES
|
|
6th EU-US Conference on Repair of Endogenous DNA Damage
|
1R13CA216985-01
|
$3,000
|
$900
|
SOBOL, ROBERT
|
UNIVERSITY OF SOUTH ALABAMA
|
|
A cell-based liquid biopsy approach for early pancreatic cancer detection
|
5F32CA196120-03
|
$57,066
|
|
BHAGWAT, NEHA
|
UNIVERSITY OF PENNSYLVANIA
|
|
A CEST-MRI Reporter Gene for Image Guided Oncolytic Virotherapy
|
5R01CA203873-02
|
$406,309
|
|
FARRAR, CHRISTIAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
A Fully Independent Real Time Treatment Verification System for Radiotherapy
|
5R44CA200168-03
|
$616,220
|
|
KAPATOES, JEFFREY
|
SUN NUCLEAR CORPORATION
|
|
A high efficiency imager for real-time lung cancer monitoring during radiotherapy
|
5R01CA188446-04
|
$768,460
|
|
BERBECO, ROSS
|
DANA-FARBER CANCER INST
|
|
A High-Throughput Model for Human Melanoma
|
5R01CA121118-09
|
$247,340
|
|
HOLMEN, SHERI
|
UNIVERSITY OF UTAH
|
|
A longitudinal assessment of frailty in young adult survivors of childhood cancer
|
5R01CA174851-04
|
$538,152
|
$538,152
|
NESS, KIRSTEN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
A Mechanistic Model of Chimeric Antigen Receptor (CAR) Signaling Predicts the Effects of Co-Stimulatory Signaling on T cell Activation
|
5F31CA200242-03
|
$44,044
|
|
ROHRS, JENNIFER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
A Narrowed Window for Targeting Metabolic Flexibility in Breast Cancer Prevention
|
5R01CA164166-05
|
$322,663
|
$161,332
|
MACLEAN, PAUL
|
UNIVERSITY OF COLORADO DENVER
|
Total relevant funding to Aging for this search: $64,694,464
|